Glutamine for the Treatment of Patients With Irritable Bowel Syndrome (AT005291)
Randomized, Placebo-Controlled Trial of Glutamine for the Treatment of Patients With Irritable Bowel Syndrome
Sponsor: Tulane University
Listed as NCT01414244, this PHASE2 trial focuses on Diarrhea-Predominant Irritable Bowel Syndrome and remains completed. Sponsored by Tulane University, it has been updated 10 times since 2010, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
May 2017 — Aug 2017 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tulane University
For direct contact, visit the study record on ClinicalTrials.gov .